NASDAQ:PAHC - Get Free Report ) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.040-1.160 for the period, compared to the consensus estimate of 1.100. The company issued revenue guidance of $980.0 million-$1.0 billion, compared to the consensus revenue estimate of $999.0 million.
Get Phibro Animal Health alerts:
Sign Up
Phibro Animal Health Price Performance NASDAQ:PAHC traded up $0.41 during trading hours on Wednesday, reaching $17.18. 130,110 shares of the company's stock were exchanged, compared to its average volume of 152,202. The company has a market capitalization of $695.79 million, a P/E ratio of 47.72, a price-to-earnings-growth ratio of 6.30 and a beta of 0.63. Phibro Animal Health has a 12 month low of $9.40 and a 12 month high of $17.44. The business's 50-day simple moving average is $13.39 and its two-hundred day simple moving average is $12.00. The company has a quick ratio of 1.60, a current ratio of 3.12 and a debt-to-equity ratio of 1.66.
Phibro Animal Health (NASDAQ:PAHC - Get Free Report ) last released its quarterly earnings data on Wednesday, February 7th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.06. The business had revenue of $249.90 million during the quarter, compared to analyst estimates of $242.91 million. Phibro Animal Health had a return on equity of 16.67% and a net margin of 1.51%. Sell-side analysts expect that Phibro Animal Health will post 1.12 EPS for the current fiscal year.
Analyst Upgrades and Downgrades Separately, StockNews.com upgraded Phibro Animal Health from a hold rating to a buy rating in a report on Tuesday, April 9th.
Read Our Latest Stock Analysis on PAHC
About Phibro Animal Health (
Get Free Report )
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Phibro Animal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phibro Animal Health wasn't on the list.
While Phibro Animal Health currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
